Assembly Biosciences - 14 Year Stock Price History | ASMB
Historical daily share price chart and data for Assembly Biosciences since 2010 adjusted for splits and dividends. The latest closing stock price for Assembly Biosciences as of December 20, 2024 is 15.21.
- The all-time high Assembly Biosciences stock closing price was 1215.00 on May 09, 2011.
- The Assembly Biosciences 52-week high stock price is 19.93, which is 31% above the current share price.
- The Assembly Biosciences 52-week low stock price is 9.12, which is 40% below the current share price.
- The average Assembly Biosciences stock price for the last 52 weeks is 14.24.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Assembly Biosciences Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2024 |
14.3167 |
9.9840 |
19.4300 |
9.5688 |
15.2100 |
54.55% |
| 2023 |
12.6612 |
16.0800 |
20.8800 |
7.7676 |
9.8412 |
-36.92% |
| 2022 |
21.4465 |
29.4000 |
29.4000 |
13.0800 |
15.6000 |
-44.21% |
| 2021 |
47.3995 |
72.4800 |
79.5600 |
25.5600 |
27.9600 |
-61.49% |
| 2020 |
204.0138 |
238.8000 |
324.4800 |
58.4400 |
72.6000 |
-70.43% |
| 2019 |
194.0036 |
276.4800 |
299.1600 |
100.3200 |
245.5200 |
-9.55% |
| 2018 |
475.6879 |
555.3600 |
769.9200 |
228.6000 |
271.4400 |
-50.01% |
| 2017 |
321.8113 |
146.2800 |
598.9200 |
146.2800 |
543.0000 |
272.43% |
| 2016 |
89.6583 |
86.2800 |
169.8000 |
54.4800 |
145.8000 |
61.78% |
| 2015 |
153.3181 |
94.5600 |
242.4000 |
87.8400 |
90.1200 |
-4.45% |
| 2014 |
102.9797 |
225.6000 |
267.6000 |
51.6000 |
94.3200 |
-58.85% |
| 2013 |
164.4384 |
143.4000 |
229.2000 |
123.0000 |
229.2000 |
76.85% |
| 2012 |
389.8670 |
479.4000 |
754.8000 |
123.6000 |
129.6000 |
-73.03% |
| 2011 |
641.0420 |
408.0000 |
1215.0000 |
360.0000 |
480.4800 |
20.97% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.100B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
